Edition:
United States

Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

120.01USD
11:00am EDT
Change (% chg)

$0.06 (+0.05%)
Prev Close
$119.95
Open
$120.35
Day's High
$120.35
Day's Low
$119.34
Volume
15,676
Avg. Vol
88,999
52-wk High
$120.51
52-wk Low
$94.58

Latest Key Developments (Source: Significant Developments)

Charles River Laboratories Q4 GAAP Loss Per Share $0.63
Tuesday, 13 Feb 2018 07:01am EST 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 RESULTS FROM CONTINUING OPERATIONS AND PROVIDES 2018 GUIDANCE.Q4 NON-GAAP EARNINGS PER SHARE $1.40.Q4 GAAP LOSS PER SHARE $0.63.Q4 REVENUE ROSE 2.5 PERCENT TO $478.5 MILLION.Q4 EARNINGS PER SHARE VIEW $1.25, REVENUE VIEW $474.6 MILLION -- THOMSON REUTERS I/B/E/S.CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $5.42 - $5.57.CHARLES RIVER LABORATORIES SEES 2018 GAAP EARNINGS PER SHARE FROM CONTINUING OPERATIONS $4.71 - $4.86.SEES 2018 REVENUE GROWTH, REPORTED, FROM CONTINUING OPERATIONS OF 7.2% TO 8.2%.FY2018 EARNINGS PER SHARE VIEW $5.58, REVENUE VIEW $1.99 BILLION -- THOMSON REUTERS I/B/E/S.CHARLES RIVER LABORATORIES - EXCLUDING MPI, 2018 EPS EXPECTED TO BENEFIT FROM HIGHER REVENUE, MODEST OPERATING. MARGIN IMPROVEMENT.CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE INCLUDES GAIN OF $0.14 ON VENTURE CAPITAL INVESTMENTS.CHARLES RIVER LABORATORIES - 2018 EARNINGS PER SHARE GUIDANCE ALSO INCLUDES GAIN OF $0.14 FOR EXCESS TAX BENEFIT ASSOCIATED WITH STOCK COMPENSATION.CHARLES RIVER LABORATORIES SEES 2018 NON-GAAP EARNINGS PER SHARE INCLUDING MPI $5.67 - $5.82.  Full Article

Charles River Laboratories To Buy MPI Research For About $800 Mln
Tuesday, 13 Feb 2018 07:00am EST 

Feb 13 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES TO ACQUIRE MPI RESEARCH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL FOR APPROXIMATELY $800 MILLION.CHARLES RIVER LABORATORIES - DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EPS BY APPROXIMATELY $0.25 IN 2018 AND APPROXIMATELY $0.60 IN 2019​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍FOR 2017, MPI IS EXPECTED TO GENERATE ANNUAL REVENUE OF APPROXIMATELY $240 MILLION​.CHARLES RIVER LABORATORIES INTERNATIONAL - ‍EXPECTS TO GENERATE OPERATIONAL SYNERGIES AS RESULT OF DEAL, WITH BENEFITS TOTALING $13 TO $16 MILLION BY END OF 2019​.CHARLES RIVER LABORATORIES - DEAL EXPECTED TO ADD $170 TO $190 MILLION TO CHARLES RIVER'S 2018 CONSOLIDATED REVENUE BASED ON ANTICIPATED TIMING OF CLOSE​.CHARLES RIVER LABORATORIES INTERNATIONAL - ‍ACQUISITION & ASSOCIATED FEES ARE EXPECTED TO BE FINANCED THROUGH AN EXPANSION OF CO'S CREDIT FACILITY & CASH​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍COMPANY IS EVALUATING FIXED-RATE DEBT FINANCING ALTERNATIVES WHICH COULD BE USED TO FINANCE ACQUISITION​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ACQUISITION IS EXPECTED TO ADD $260 TO $280 MILLION TO 2019 CONSOLIDATED REVENUE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - DEAL,ASSOCIATED FEES EXPECTED TO BE FINANCED THROUGH EXPANSION OF CHARLES RIVER'S CREDIT FACILITY, CASH​.  Full Article

Charles River Laboratories Acquires KWS Biotest for GBP 15 Mln
Thursday, 11 Jan 2018 07:00am EST 

Jan 11 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES ACQUIRES KWS BIOTEST.CHARLES RIVER LABORATORIES INTERNATIONAL INC - PURCHASE PRICE WAS APPROXIMATELY £15 MILLION IN CASH.CHARLES RIVER LABORATORIES INTERNATIONAL INC - ‍ TRANSACTION INCLUDES A POTENTIAL ADDITIONAL PAYMENT OF UP TO £3 MILLION BASED ON FUTURE PERFORMANCE​.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.CHARLES RIVER LABORATORIES INTERNATIONAL INC - TRANSACTION IS NOT EXPECTED TO BE MATERIAL TO 2018 GAAP OR NON-GAAP RESULTS FROM OPERATIONS.  Full Article

Charles River Laboratories Says New Tax Legislation Expected To Be Effectively Neutral To Co's GAAP, Non-GAAP EPS In 2018
Tuesday, 9 Jan 2018 08:19am EST 

Jan 9 (Reuters) - Charles River Laboratories International Inc ::CHARLES RIVER LABORATORIES SAYS NEW TAX LEGISLATION EXPECTED TO BE EFFECTIVELY NEUTRAL TO CO'S GAAP AND NON-GAAP EPS IN 2018 - SEC FILING.  Full Article

Charles River Laboratories reports Q3 non-GAAP EPS of $1.30
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Charles River Laboratories International Inc ::Updates 2017 guidance​.Announces third-quarter 2017 results from continuing operations.Q3 non-GAAP earnings per share $1.30.Q3 GAAP earnings per share $1.09.Q3 revenue $464.2 million versus I/B/E/S view $458.7 million.Q3 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Sees ‍2017 revenue growth, reported 9.75 percent - 10.5 percent​.Sees ‍2017 non-GAAP EPS estimate $5.08 - $5.18​.Sees ‍2017 GAAP EPS estimate $3.95 - $4.05​.FY2017 earnings per share view $5.10, revenue view $1.85 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River announces expansion of in vitro oncology services
Thursday, 26 Oct 2017 08:00am EDT 

Oct 26 (Reuters) - Charles River Laboratories International Inc :Charles River announces expansion of in vitro oncology services.Charles River Laboratories International Inc says partnership with InSphero AG, supplier of 3D solutions for in vitro drug discovery and development​.Charles River Laboratories International Inc - ‍through partnership, co will license its collection of patient-derived xenograft tumors to InSphero​.  Full Article

Charles River Laboratories posts Q2 adj. earnings $1.29/shr
Wednesday, 9 Aug 2017 07:00am EDT 

Aug 9 (Reuters) - Charles River Laboratories International Inc :Charles River Laboratories announces second-quarter 2017 results from continuing operations.Q2 non-GAAP earnings per share $1.29.Q2 GAAP earnings per share $1.12.Q2 revenue $469.1 million versus I/B/E/S view $458 million.Q2 earnings per share view $1.22 -- Thomson Reuters I/B/E/S.Charles River Laboratories International Inc sees 2017 GAAP EPS estimate $4.18-$4.33.Charles River Laboratories International Inc sees 2017 non-GAAP EPS estimate $5.00- $5.15.Charles River Laboratories International Inc sees 2017 revenue growth, organic 7.0 pct - 8.5 pct.Q2 earnings per share view $1.22, revenue view $458.0 million -- Thomson Reuters I/B/E/S.Fy2017 earnings per share view $5.10, revenue view $1.83 billion -- Thomson Reuters I/B/E/S.  Full Article

Charles River Laboratories acquires Brains On-Line
Monday, 7 Aug 2017 07:30am EDT 

Aug 7 (Reuters) - Charles River Laboratories International Inc :Charles river laboratories acquires Brains On-Line.Charles River Laboratories International Inc - ‍purchase price was approximately EUR 18 million in cash​.Charles River Laboratories - ‍In addition to initial purchase price, deal includes potential additional payments of up to eur 6.7 million.Charles River Laboratories International Inc says ‍it has acquired Brains On-Line, a contract research organization​.  Full Article

Charles River Laboratories' Board increase size of board from nine to ten
Thursday, 6 Jul 2017 07:00am EDT 

July 6 (Reuters) - Charles River Laboratories International Inc :Charles River Laboratories International - on July 1, board of directors of co increased size of board from nine to ten - SEC filing.  Full Article

Charles River Laboratories reports Q1 non-GAAP earnings per share $1.29
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Charles River Laboratories International Inc : :Charles river laboratories announces first-quarter 2017 results from continuing operations.Q1 non-GAAP earnings per share $1.29.Q1 GAAP earnings per share $0.97.Q1 revenue $445.8 million versus I/B/E/S view $437.1 million.Q1 earnings per share view $1.14 -- Thomson Reuters I/B/E/S.Charles river laboratories international inc sees 2017 revenue growth, reported 7.5pct - 9.0pct.Charles River Laboratories International Inc sees 2017 non-gaap eps estimate $5.00 - $5.15.Sees 2017 GAAP eps estimate of $4.18-$4.33.Charles River Laboratories International Inc - company is maintaining its revenue guidance for 2017.FY2017 earnings per share view $5.06, revenue view $1.83 billion -- Thomson Reuters I/B/E/S.Sees 2017 revenue growth, organic of 7.0pct - 8.5pct.Sees 2017 non-GAAP EPS estimate of $5.00 - $5.15.  Full Article